Coivas Tirzepatide Review: Cost, a Named Clinical Provider & Honest Verdict (2026)

Coivas: it names its clinical provider — Arora Health & Aesthetics, LLC — directly on the site, a genuine transparency signal, alongside a $149/month semaglutide figure consistent with its published quarterly-plan pricing. Every fact here comes from the company's own published program.

What Coivas is

Coivas is an all-inclusive GLP-1 telehealth service, operated by WellVi LLC (d/b/a Coivas), with prescriptions written through Arora Health & Aesthetics, LLC — a named clinical provider. It cites USP 797 / NABP-accredited pharmacies, is available in all 50 states, and offers 24/7 support with HSA/FSA eligibility.

What Coivas costs

Compounded semaglutide starts from $149/month on the quarterly plan. Tirzepatide starts from $229/month on the same quarterly commitment — but the monthly plan costs more ($179 for semaglutide, $289 for tirzepatide), so confirm which commitment length your quote reflects. Pricing is all-inclusive: one number covers the doctor consult, prescription, shipping, and support.

The brand-vs-compounded question

Coivas dispenses compounded tirzepatide only — no brand-name Wegovy, Zepbound, Mounjaro, or Ozempic option. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

Coivas's real strengths: a named clinical provider (Arora Health & Aesthetics), all-inclusive pricing in one number, and all-50-state availability, 24/7 support, HSA/FSA eligibility, and approvals typically under 2 hours with a refund if no provider visit occurs. The trade-offs: dispensing pharmacies are described only by category (503A/503B, NABP-accredited) rather than named individually, the lower quarterly price requires a 3-month commitment, the money-back guarantee carries strict adherence conditions with no partial refunds, and it's compounded-injectable only with binding NY arbitration in the terms. As with any GLP-1 program, read the refund conditions closely before committing; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Coivas's named clinical provider and all-inclusive pricing are genuine positives, but the lowest advertised rate requires a quarterly commitment, and the money-back guarantee's strict conditions are worth reading before assuming it protects you the way it sounds. If you want a similarly named-provider platform with a simpler refund policy, compare it against Care Clinics or CoreAge Rx. For a tirzepatide-focused provider with a genuinely named physician founder, see Emerge Weight Loss. For another provider using the same Arora Health & Aesthetics clinical network, built specifically for menopause care, see Kina. And for a third provider from the same Arora practice, with a broader dose ladder and a sublingual option, see Lumora. For a provider whose clinical care runs through a network flagged in a 2026 StatNews analysis of FDA-warned GLP-1 companies, though the provider itself hasn't been warned, see Remi Meds. See our best tirzepatide providers ranking for the full field.